{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:47:24Z","timestamp":1789238844752,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2304500"],"award-info":[{"award-number":["2022YFC2304500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2021YFA1301104"],"award-info":[{"award-number":["2021YFA1301104"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"DOI":"10.1007\/s12519-026-01056-z","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:18:23Z","timestamp":1781371103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transplantation of encapsulated fecal microbiota: research progress and future trends"],"prefix":"10.1007","author":[{"given":"Mei-Le","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-9181","authenticated-orcid":false,"given":"Hai-Nv","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55758","volume":"6","author":"MD Sims","year":"2023","unstructured":"Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023;6:e2255758. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55758.","journal-title":"JAMA Netw Open"},{"key":"1056_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020009","volume":"8","author":"C Nicco","year":"2020","unstructured":"Nicco C, Paule A, Konturek P, Edeas M. From donor to patient: collection, preparation and cryopreservation of fecal samples for fecal microbiota transplantation. Diseases. 2020;8:9. https:\/\/doi.org\/10.3390\/diseases8020009.","journal-title":"Diseases"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/gutjnl-2023-329515","volume":"73","author":"RW Ng","year":"2024","unstructured":"Ng RW, Dharmaratne P, Wong S, Hawkey P, Chan P, Ip M. Revisiting the donor screening protocol of faecal microbiota transplantation (FMT): a systematic review. Gut. 2024;73:1029\u201331. https:\/\/doi.org\/10.1136\/gutjnl-2023-329515.","journal-title":"Gut"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Bloom PP, Soto MT, Mansour MK, Sater MRA, Huntley MH, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1910437.","journal-title":"N Engl J Med"},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/IDR.S419243","volume":"17","author":"L Monday","year":"2024","unstructured":"Monday L, Tillotson G, Chopra T. Microbiota-based live biotherapeutic products for Clostridioides difficile infection- the devil is in the details. Infect Drug Resist. 2024;17:623\u201339. https:\/\/doi.org\/10.2147\/IDR.S419243.","journal-title":"Infect Drug Resist"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2106516.","journal-title":"N Engl J Med"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.2017.17077","volume":"318","author":"D Kao","year":"2017","unstructured":"Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral capsule\u2013vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985. https:\/\/doi.org\/10.1001\/jama.2017.17077.","journal-title":"JAMA"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2022.09.008","volume":"21","author":"BP Vaughn","year":"2023","unstructured":"Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, et al. Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection. Clin Gastroenterol Hepatol. 2023;21:1330-7.e2. https:\/\/doi.org\/10.1016\/j.cgh.2022.09.008.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10620-020-06185-7","volume":"66","author":"D Ramai","year":"2021","unstructured":"Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, et al. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Dig Dis Sci. 2021;66:369\u201380. https:\/\/doi.org\/10.1007\/s10620-020-06185-7.","journal-title":"Dig Dis Sci"},{"key":"1056_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MCG.0000000000001495","volume":"55","author":"C Du","year":"2021","unstructured":"Du C, Luo Y, Walsh S, Grinspan A. Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:300\u20138. https:\/\/doi.org\/10.1097\/MCG.0000000000001495.","journal-title":"J Clin Gastroenterol"},{"key":"1056_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0680-9","volume":"14","author":"I Youngster","year":"2016","unstructured":"Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14:134. https:\/\/doi.org\/10.1186\/s12916-016-0680-9.","journal-title":"BMC Med"},{"key":"1056_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205064","volume":"13","author":"ZD Jiang","year":"2018","unstructured":"Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS ONE. 2018;13:e0205064. https:\/\/doi.org\/10.1371\/journal.pone.0205064.","journal-title":"PLoS ONE"},{"key":"1056_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1854640","volume":"12","author":"JE Green","year":"2020","unstructured":"Green JE, Davis JA, Berk M, Hair C, Loughman A, Castle D, et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes. 2020;12:1854640. https:\/\/doi.org\/10.1080\/19490976.2020.1854640.","journal-title":"Gut Microbes"},{"key":"1056_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251369624","volume":"18","author":"J Chapon","year":"2025","unstructured":"Chapon J, Scanzi J, Sokol H, Pereira B, Buisson A. Efficacy of different modalities of faecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis. Therap Adv Gastroenterol. 2025;18:17562848251369624. https:\/\/doi.org\/10.1177\/17562848251369624.","journal-title":"Therap Adv Gastroenterol"},{"key":"1056_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.827395","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022;12:827395. https:\/\/doi.org\/10.3389\/fcimb.2022.827395.","journal-title":"Front Cell Infect Microbiol"},{"key":"1056_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.826114","volume":"12","author":"HF Halaweish","year":"2022","unstructured":"Halaweish HF, Boatman S, Staley C. Encapsulated fecal microbiota transplantation: development, efficacy, and clinical application. Front Cell Infect Microbiol. 2022;12:826114. https:\/\/doi.org\/10.3389\/fcimb.2022.826114.","journal-title":"Front Cell Infect Microbiol"},{"key":"1056_CR17","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.4663","volume":"6","author":"S Fareed","year":"2018","unstructured":"Fareed S, Sarode N, Stewart FJ, Malik A, Laghaie E, Khizer S, et al. Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children. PeerJ. 2018;6:e4663. https:\/\/doi.org\/10.7717\/peerj.4663.","journal-title":"PeerJ"},{"key":"1056_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02622","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, Gao X, Hu H, Xiao Y, Li D, Yu G, et al. Clinical efficacy and microbiome changes following fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Front Microbiol. 2018;9:2622. https:\/\/doi.org\/10.3389\/fmicb.2018.02622.","journal-title":"Front Microbiol"},{"key":"1056_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10122450","volume":"10","author":"KM Tun","year":"2022","unstructured":"Tun KM, Hsu M, Batra K, Lo CH, Laeeq T, Vongsavath T, et al. Efficacy and safety of fecal microbiota transplantation in treatment of Clostridioides difficile infection among pediatric patients: a systematic review and meta-analysis. Microorganisms. 2022;10:2450. https:\/\/doi.org\/10.3390\/microorganisms10122450.","journal-title":"Microorganisms"},{"key":"1056_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cgh.2019.04.037","volume":"18","author":"MR Nicholson","year":"2020","unstructured":"Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children. Clin Gastroenterol Hepatol. 2020;18:612-9.e1. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.037.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1056_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/apt.14201","volume":"46","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479\u201393. https:\/\/doi.org\/10.1111\/apt.14201.","journal-title":"Aliment Pharmacol Ther"},{"key":"1056_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/MPG.0000000000003714","volume":"76","author":"KR Conover","year":"2023","unstructured":"Conover KR, Absah I, Ballal S, Brumbaugh D, Cho S, Cardenas MC, et al. Fecal microbiota transplantation for Clostridioides difficile infection in immunocompromised pediatric patients. J Pediatr Gastroenterol Nutr. 2023;76:440\u20136. https:\/\/doi.org\/10.1097\/MPG.0000000000003714.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1056_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13875","volume":"312","author":"I Youngster","year":"2014","unstructured":"Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772. https:\/\/doi.org\/10.1001\/jama.2014.13875.","journal-title":"JAMA"},{"key":"1056_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05832-1","volume":"23","author":"B Zou","year":"2025","unstructured":"Zou B, Liu S, Dong C, Shen H, Lv Y, He J, et al. Fecal microbiota transplantation restores gut microbiota diversity in children with active Crohn\u2019s disease: a prospective trial. J Transl Med. 2025;23:288. https:\/\/doi.org\/10.1186\/s12967-024-05832-1.","journal-title":"J Transl Med"},{"key":"1056_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu15071742","volume":"15","author":"H Hoelz","year":"2023","unstructured":"Hoelz H, Heetmeyer J, Tsakmaklis A, Hiergeist A, Siebert K, De Zen F, et al. Is autologous fecal microbiota transfer after exclusive enteral nutrition in pediatric Crohn\u2019s disease patients rational and feasible? Data from a feasibility test. Nutrients. 2023;15:1742. https:\/\/doi.org\/10.3390\/nu15071742.","journal-title":"Nutrients"},{"key":"1056_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MPG.0b013e318292fa0d","volume":"56","author":"S Kunde","year":"2013","unstructured":"Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:597\u2013601. https:\/\/doi.org\/10.1097\/MPG.0b013e318292fa0d.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ibd\/izx035","volume":"24","author":"A Goyal","year":"2018","unstructured":"Goyal A, Yeh A, Bush BR, Firek BA, Siebold LM, Rogers MB, et al. Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:410\u201321. https:\/\/doi.org\/10.1093\/ibd\/izx035.","journal-title":"Inflamm Bowel Dis"},{"key":"1056_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11051272","volume":"11","author":"M Hsu","year":"2023","unstructured":"Hsu M, Tun KM, Batra K, Haque L, Vongsavath T, Hong AS. Safety and efficacy of fecal microbiota transplantation in treatment of inflammatory bowel disease in the pediatric population: a systematic review and meta-analysis. Microorganisms. 2023;11:1272. https:\/\/doi.org\/10.3390\/microorganisms11051272.","journal-title":"Microorganisms"},{"key":"1056_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8941340","volume":"2018","author":"H Fang","year":"2018","unstructured":"Fang H, Fu L, Wang J. Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. BioMed Res Int. 2018;2018:8941340. https:\/\/doi.org\/10.1155\/2018\/8941340.","journal-title":"BioMed Res Int"},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.2147\/NDT.S488001","volume":"20","author":"Y Li","year":"2024","unstructured":"Li Y, Xiao P, Ding H, Wang H, Xu Q, Wang R, et al. Fecal microbiota transplantation in children with autism. Neuropsychiatr Dis Treat. 2024;20:2391\u2013400. https:\/\/doi.org\/10.2147\/NDT.S488001.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1056_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-025-03858-z","volume":"25","author":"P Xiao","year":"2025","unstructured":"Xiao P, Li Y, Li X, Ge T, Li D, Xu Q, et al. Long-term safety of fecal microbiota transplantation in Chinese children from 2013 to 2023: a single-center retrospective study. BMC Microbiol. 2025;25:152. https:\/\/doi.org\/10.1186\/s12866-025-03858-z.","journal-title":"BMC Microbiol"},{"key":"1056_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061393","volume":"13","author":"EA Bieganska","year":"2025","unstructured":"Bieganska EA, Kosinski P, Wolski M. Possible applications of fecal microbiota transplantation in the pediatric population: a systematic review. Biomedicines. 2025;13:1393. https:\/\/doi.org\/10.3390\/biomedicines13061393.","journal-title":"Biomedicines"},{"key":"1056_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1296","volume":"12","author":"SP Fabara","year":"2025","unstructured":"Fabara SP, Alok A, Kalsi H, Bakhit M, Thomas S. P-1108. Efficacy and safety of investigational therapeutic microbiome SER-109 in recurrent Clostridioides difficile infection: a systematic review. Open Forum Infect Dis. 2025;12:ofae631.1296. https:\/\/doi.org\/10.1093\/ofid\/ofae631.1296.","journal-title":"Open Forum Infect Dis"},{"key":"1056_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.332","volume":"12","author":"M Sims","year":"2025","unstructured":"Sims M, Kraft CS, Huang E, von Moltke L, Hasson B, von Eynatten M, et al. P-127. Safety and efficacy of fecal microbiota spores, live-brpk (formerly SER-109) in patients with recurrent Clostridioides difficile infection (CDI): subgroup analysis by number of prior CDI recurrences from an integrated analysis of phase 3 trials. Open Forum Infect Dis. 2025;12:ofae631.332. https:\/\/doi.org\/10.1093\/ofid\/ofae631.332.","journal-title":"Open Forum Infect Dis"},{"key":"1056_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11091234","volume":"11","author":"S Khanna","year":"2022","unstructured":"Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, et al. SER-109: an oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics. 2022;11:1234. https:\/\/doi.org\/10.3390\/antibiotics11091234.","journal-title":"Antibiotics"},{"key":"1056_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41591-025-04076-w","volume":"32","author":"JA Bryant","year":"2026","unstructured":"Bryant JA, Vuli\u0107 M, Walsh EA, Allen EG Jr, Beauchemin NJ, Chafee ME, et al. The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med. 2026;32:186\u201396. https:\/\/doi.org\/10.1038\/s41591-025-04076-w.","journal-title":"Nat Med"},{"key":"1056_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241253089","volume":"17","author":"HL DuPont","year":"2024","unstructured":"DuPont HL, DuPont AW, Tillotson GS. Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therap Adv Gastroenterol. 2024;17:17562848241253089. https:\/\/doi.org\/10.1177\/17562848241253089.","journal-title":"Therap Adv Gastroenterol"},{"key":"1056_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/cid\/ciad636","volume":"78","author":"TJ Straub","year":"2024","unstructured":"Straub TJ, Lombardo MJ, Bryant JA, Diao L, Lodise TP, Freedberg DE, et al. Impact of a purified microbiome therapeutic on abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection. Clin Infect Dis. 2024;78:833\u201341. https:\/\/doi.org\/10.1093\/cid\/ciad636.","journal-title":"Clin Infect Dis"},{"key":"1056_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiv766","volume":"214","author":"S Khanna","year":"2016","unstructured":"Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173\u201381. https:\/\/doi.org\/10.1093\/infdis\/jiv766.","journal-title":"J Infect Dis"},{"key":"1056_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac448","volume":"9","author":"C McChalicher","year":"2022","unstructured":"McChalicher C, Abdulaziz A, Zhou SS, Lombardo MJ, Hasson B, Auni\u0146\u0161 JG, et al. Manufacturing process of SER-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool. Open Forum Infect Dis. 2022;9:ofac448. https:\/\/doi.org\/10.1093\/ofid\/ofac448.","journal-title":"Open Forum Infect Dis"},{"key":"1056_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16476","volume":"328","author":"SH Cohen","year":"2022","unstructured":"Cohen SH, Louie TJ, Sims M, Wang EEL, Memisoglu A, McGovern BH, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022;328:2062. https:\/\/doi.org\/10.1001\/jama.2022.16476.","journal-title":"JAMA"},{"key":"1056_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.53570","volume":"6","author":"KW Garey","year":"2023","unstructured":"Garey KW, Jo J, Gonzales-Luna AJ, Lapin B, Deshpande A, Wang E, et al. Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2253570. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.53570.","journal-title":"JAMA Netw Open"},{"key":"1056_CR43","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","volume":"72","author":"BH McGovern","year":"2021","unstructured":"McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72:2132\u201340. https:\/\/doi.org\/10.1093\/cid\/ciaa387.","journal-title":"Clin Infect Dis"},{"key":"1056_CR44","doi-asserted-by":"publisher","first-page":"e00045","DOI":"10.1128\/mSphere.00045-15","volume":"1","author":"CM Theriot","year":"2016","unstructured":"Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere. 2016;1:e00045-e115. https:\/\/doi.org\/10.1128\/mSphere.00045-15.","journal-title":"mSphere"},{"key":"1056_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.anaerobe.2016.05.003","volume":"41","author":"JA Winston","year":"2016","unstructured":"Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe. 2016;41:44\u201350. https:\/\/doi.org\/10.1016\/j.anaerobe.2016.05.003.","journal-title":"Anaerobe"},{"key":"1056_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00191","volume":"6","author":"N Studer","year":"2016","unstructured":"Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, et al. Functional intestinal bile acid 7\u03b1-dehydroxylation by Clostridium scindens associated with protection from Clostridium difficile infection in a gnotobiotic mouse model. Front Cell Infect Microbiol. 2016;6:191. https:\/\/doi.org\/10.3389\/fcimb.2016.00191.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"1056_CR47","doi-asserted-by":"publisher","first-page":"e00039","DOI":"10.1128\/jb.00039-20","volume":"202","author":"AD Reed","year":"2020","unstructured":"Reed AD, Nethery MA, Stewart A, Barrangou R, Theriot CM. Strain-dependent inhibition of Clostridioides difficile by commensal Clostridia carrying the bile acid-inducible (bai) operon. J Bacteriol. 2020;202(11):e00039-e120. https:\/\/doi.org\/10.1128\/jb.00039-20.","journal-title":"J Bacteriol"},{"key":"1056_CR48","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1021\/ja061831t","volume":"129","author":"ML Cable","year":"2007","unstructured":"Cable ML, Kirby JP, Sorasaenee K, Gray HB, Ponce A. Bacterial spore detection by [Tb3+(macrocycle)(dipicolinate)] luminescence. J Am Chem Soc. 2007;129:1474\u20135. https:\/\/doi.org\/10.1021\/ja061831t.","journal-title":"J Am Chem Soc"},{"key":"1056_CR49","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/1462-2920.15343","volume":"23","author":"JE Rattray","year":"2021","unstructured":"Rattray JE, Chakraborty A, Li C, Elizondo G, John N, Wong M, et al. Sensitive quantification of dipicolinic acid from bacterial endospores in soils and sediments. Environ Microbiol. 2021;23:1397\u2013406. https:\/\/doi.org\/10.1111\/1462-2920.15343.","journal-title":"Environ Microbiol"},{"key":"1056_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15403\/jgld-5990","volume":"34","author":"T Urbonas","year":"2025","unstructured":"Urbonas T, Petrauskas D, Kiudelis V, Jonaitis L, Skieceviciene J, Gedgaudas R, et al. Fecal microbiome transplantation for recurrent CDI: treatment efficacy and safety with oral capsules. J Gastrointest Liver Dis. 2025;34:199\u2013204. https:\/\/doi.org\/10.15403\/jgld-5990.","journal-title":"J Gastrointest Liver Dis"},{"key":"1056_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107561","volume":"66","author":"L Daneri","year":"2025","unstructured":"Daneri L, Urbano A, Escudero-S\u00e1nchez R, Halperin AV, Moreno-Blanco A, Corbacho MD, et al. Lyophilised fecal microbiota transfer in capsules for recurrent Clostridioides difficile infection. Int J Antimicrob Agents. 2025;66:107561. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107561.","journal-title":"Int J Antimicrob Agents"},{"key":"1056_CR52","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.214","volume":"3","author":"M Sims","year":"2023","unstructured":"Sims M, Silverman M, Louie T, Wang E, Kraft C, Ramesh M, et al. Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection. Antimicrob Steward Healthc Epidemiol. 2023;3:s5. https:\/\/doi.org\/10.1017\/ash.2023.214.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"1056_CR53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2020.08.065","volume":"160","author":"V Ronan","year":"2021","unstructured":"Ronan V, Yeasin R, Claud EC. Childhood development and the microbiome\u2014the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology. 2021;160:495\u2013506. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.065.","journal-title":"Gastroenterology"},{"key":"1056_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1597206","volume":"12","author":"T Bankole","year":"2025","unstructured":"Bankole T, Li Y. The early-life gut microbiome in common pediatric diseases: roles and therapeutic implications. Front Nutr. 2025;12:1597206. https:\/\/doi.org\/10.3389\/fnut.2025.1597206.","journal-title":"Front Nutr"},{"key":"1056_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57734-z","volume":"10","author":"D Radjabzadeh","year":"2020","unstructured":"Radjabzadeh D, Boer CG, Beth SA, van der Wal P, Kiefte-De Jong JC, Jansen MAE, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Sci Rep. 2020;10:1040. https:\/\/doi.org\/10.1038\/s41598-020-57734-z.","journal-title":"Sci Rep"},{"key":"1056_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1042526","volume":"13","author":"S Horvat","year":"2022","unstructured":"Horvat S, Mahnic A, Makuc D, Pe\u010dnik K, Plavec J, Rupnik M. Children gut microbiota exhibits a different composition and metabolic profile after in vitro exposure to Clostridioides difficile and increases its sporulation. Front Microbiol. 2022;13:1042526. https:\/\/doi.org\/10.3389\/fmicb.2022.1042526.","journal-title":"Front Microbiol"},{"key":"1056_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.651081","volume":"12","author":"IM Vasilescu","year":"2022","unstructured":"Vasilescu IM, Chifiriuc MC, Pircalabioru GG, Filip R, Bolocan A, Laz\u0103r V, et al. Gut dysbiosis and Clostridioides difficile infection in neonates and adults. Front Microbiol. 2022;12:651081. https:\/\/doi.org\/10.3389\/fmicb.2021.651081.","journal-title":"Front Microbiol"},{"key":"1056_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-023-00421-4","volume":"9","author":"Q Wu","year":"2023","unstructured":"Wu Q, Boonma P, Badu S, Yalcinkaya N, So SY, Garey KW, et al. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. npj Biofilms Microbiomes. 2023;9:54. https:\/\/doi.org\/10.1038\/s41522-023-00421-4.","journal-title":"npj Biofilms Microbiomes"},{"key":"1056_CR59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-4939-6361-4_19","volume":"1476","author":"E Perez","year":"2016","unstructured":"Perez E, Lee CH, Petrof EO. A practical method for preparation of fecal microbiota transplantation. Methods Mol Biol. 2016;1476:259\u201367. https:\/\/doi.org\/10.1007\/978-1-4939-6361-4_19.","journal-title":"Methods Mol Biol"},{"key":"1056_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.13376\/j.cbls\/2017089","volume":"29","author":"F Zhang","year":"2017","unstructured":"Zhang F, Long C, Li P. The holistic integrative view on the system of fecal microbiota transplantation. Chin Bull Life Sci. 2017;29:651\u20139. https:\/\/doi.org\/10.13376\/j.cbls\/2017089.","journal-title":"Chin Bull Life Sci"},{"key":"1056_CR61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13238-019-00684-8","volume":"11","author":"T Zhang","year":"2020","unstructured":"Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: Clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11:251\u201366. https:\/\/doi.org\/10.1007\/s13238-019-00684-8.","journal-title":"Protein Cell"},{"key":"1056_CR62","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1111\/1751-7915.14074","volume":"15","author":"G Lu","year":"2022","unstructured":"Lu G, Wang W, Li P, Wen Q, Cui B, Zhang F. Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery. Microb Biotechnol. 2022;15:2439\u201349. https:\/\/doi.org\/10.1111\/1751-7915.14074.","journal-title":"Microb Biotechnol"},{"key":"1056_CR63","unstructured":"Ferring Pharmaceuticals USA. Ferring receives U.S. FDA approval for REBYOTA\u2122 (fecal microbiota, live-jslm)\u2014a novel first-in-class microbiota-based live biotherapeutic. 2022. https:\/\/www.ferringusa.com\/ferring-receives-us-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic\/. Accessed 21 Apr 2026."},{"key":"1056_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/civ938","volume":"62","author":"R Orenstein","year":"2016","unstructured":"Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62:596\u2013602. https:\/\/doi.org\/10.1093\/cid\/civ938.","journal-title":"Clin Infect Dis"},{"key":"1056_CR65","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82:1527\u201338. https:\/\/doi.org\/10.1007\/s40265-022-01797-x.","journal-title":"Drugs"},{"key":"1056_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-024-02006-7","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA. SER-109 (VOWST\u2122): a review in the prevention of recurrent Clostridioides difficile infection. Drugs. 2024;84:329\u201336. https:\/\/doi.org\/10.1007\/s40265-024-02006-7.","journal-title":"Drugs"},{"key":"1056_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13050436","volume":"13","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hunt A, Danziger L, Drwiega EN. A comparison of currently available and investigational fecal microbiota transplant products for recurrent Clostridioides difficile infection. Antibiotics. 2024;13:436. https:\/\/doi.org\/10.3390\/antibiotics13050436.","journal-title":"Antibiotics"},{"key":"1056_CR68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.09.030","volume":"168","author":"JR Allegretti","year":"2025","unstructured":"Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, et al. Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial. Gastroenterology. 2025;168:357-66.e3. https:\/\/doi.org\/10.1053\/j.gastro.2024.09.030.","journal-title":"Gastroenterology"},{"key":"1056_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/BTT.S486372","volume":"19","author":"H Baydoun","year":"2025","unstructured":"Baydoun H, Hussain N, Wu KO, Kelly CR, Fischer M. What\u2019s new and what\u2019s next in fecal microbiota transplantation? Biologics. 2025;19:481\u201396. https:\/\/doi.org\/10.2147\/BTT.S486372.","journal-title":"Biologics"},{"key":"1056_CR70","doi-asserted-by":"publisher","first-page":"e1613","DOI":"10.1093\/cid\/ciaa1430","volume":"73","author":"S Khanna","year":"2021","unstructured":"Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients\u2019 microbiomes in a phase 1 study for recurrent Clostridioides difficile infections. Clin Infect Dis. 2021;73:e1613\u201320. https:\/\/doi.org\/10.1093\/cid\/ciaa1430.","journal-title":"Clin Infect Dis"},{"key":"1056_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1430724","volume":"15","author":"H Duo","year":"2024","unstructured":"Duo H, Yang Y, Zhang G, Chen Y, Cao Y, Luo L, et al. Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials. Front Pharmacol. 2024;15:1430724. https:\/\/doi.org\/10.3389\/fphar.2024.1430724.","journal-title":"Front Pharmacol"},{"key":"1056_CR72","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","volume":"30","author":"M Dsouza","year":"2022","unstructured":"Dsouza M, Menon R, Crossette E, Bhattarai SK, Schneider J, Kim YG, et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe. 2022;30:583-98.e8. https:\/\/doi.org\/10.1016\/j.chom.2022.03.016.","journal-title":"Cell Host Microbe"},{"key":"1056_CR73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329:1356. https:\/\/doi.org\/10.1001\/jama.2023.4314.","journal-title":"JAMA"},{"key":"1056_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000650","volume":"9","author":"PP Bloom","year":"2025","unstructured":"Bloom PP, Bassis CM, Crossette E, Silber JL, Norman JM, Young VB, et al. Safety and efficacy of a defined bacterial consortium, VE303, to treat HE. Hepatol Commun. 2025;9:e0650. https:\/\/doi.org\/10.1097\/HC9.0000000000000650.","journal-title":"Hepatol Commun"},{"key":"1056_CR75","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(21)00007-8","volume":"6","author":"D Kao","year":"2021","unstructured":"Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, et al. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol. 2021;6:282\u201391. https:\/\/doi.org\/10.1016\/S2468-1253(21)00007-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1056_CR76","doi-asserted-by":"publisher","DOI":"10.2196\/31439","volume":"10","author":"A Chinna Meyyappan","year":"2021","unstructured":"Chinna Meyyappan A, Sgarbossa C, Vazquez G, Bond DJ, M\u00fcller DJ, Milev R. The safety and efficacy of microbial ecosystem therapeutic-2 in people with major depression: protocol for a phase 2, double-blind, placebo-controlled study. JMIR Res Protoc. 2021;10:e31439. https:\/\/doi.org\/10.2196\/31439.","journal-title":"JMIR Res Protoc"},{"key":"1056_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13248-4","volume":"12","author":"MM O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell MM, Hegarty JW, Healy B, Schulz S, Walsh CJ, Hill C, et al. Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities. Sci Rep. 2022;12:9283. https:\/\/doi.org\/10.1038\/s41598-022-13248-4.","journal-title":"Sci Rep"},{"key":"1056_CR78","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.14309\/01.ajg.0000950388.31990.65","volume":"118","author":"JR Allegretti","year":"2023","unstructured":"Allegretti JR, Gupta R, Aguilar H, Pullman J, Quintas M, Stevens AC, et al. S187 ADS024, a Bacillus velezensis strain, for prevention of recurrence of Clostridioides difficile infection: Results from a randomized, placebo-controlled, double-blind, Phase 1b study. Am J Gastroenterol. 2023;118:S141\u20132. https:\/\/doi.org\/10.14309\/01.ajg.0000950388.31990.65.","journal-title":"Am J Gastroenterol"},{"key":"1056_CR79","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4291\/wjgp.v14.i4.71","volume":"14","author":"CK Murphy","year":"2023","unstructured":"Murphy CK, O\u2019Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, et al. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo. World J Gastrointest Pathophysiol. 2023;14:71\u201385. https:\/\/doi.org\/10.4291\/wjgp.v14.i4.71.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"1056_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-025-04417-w","volume":"207","author":"S Sadhu","year":"2025","unstructured":"Sadhu S, Paul T, Yadav N. Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study. Arch Microbiol. 2025;207:213. https:\/\/doi.org\/10.1007\/s00203-025-04417-w.","journal-title":"Arch Microbiol"},{"key":"1056_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-025-02046-5","volume":"13","author":"S Ji","year":"2025","unstructured":"Ji S, Ahmad F, Peng B, Yang Y, Su M, Zhao X, et al. Engrafting gut bacteriophages have potential to modulate microbial metabolism in fecal microbiota transplantation. Microbiome. 2025;13:149. https:\/\/doi.org\/10.1186\/s40168-025-02046-5.","journal-title":"Microbiome"},{"key":"1056_CR82","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.copbio.2020.11.003","volume":"68","author":"BR Lenneman","year":"2021","unstructured":"Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021;68:151\u20139. https:\/\/doi.org\/10.1016\/j.copbio.2020.11.003.","journal-title":"Curr Opin Biotechnol"},{"key":"1056_CR83","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1136\/gutjnl-2019-320005","volume":"69","author":"TS Rasmussen","year":"2020","unstructured":"Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mej\u00eda JL, Zuffa S, Swann JR, et al. Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model. Gut. 2020;69:2122\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2019-320005.","journal-title":"Gut"},{"key":"1056_CR84","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1111\/jgh.15996","volume":"37","author":"JG Wang","year":"2022","unstructured":"Wang JG, Liang Q, Dou HH, Ou Y. The global incidence of adverse events associated with fecal microbiota transplantation in children over the past 20 years: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:2031\u20138. https:\/\/doi.org\/10.1111\/jgh.15996.","journal-title":"J Gastroenterol Hepatol"},{"key":"1056_CR85","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s10620-024-08351-7","volume":"69","author":"MJ Sadowsky","year":"2024","unstructured":"Sadowsky MJ, Matson M, Mathai PP, Pho M, Staley C, Evert C, et al. Successful treatment of recurrent Clostridioides difficile infection using a novel, drinkable, oral formulation of fecal microbiota. Dig Dis Sci. 2024;69:1778\u201384. https:\/\/doi.org\/10.1007\/s10620-024-08351-7.","journal-title":"Dig Dis Sci"},{"key":"1056_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122961","volume":"639","author":"A Rakotonirina","year":"2023","unstructured":"Rakotonirina A, Galperine T, Audry M, Kroemer M, Baliff A, Carrez L, et al. Dry alginate beads for fecal microbiota transplantation: from model strains to fecal samples. Int J Pharm. 2023;639:122961. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122961.","journal-title":"Int J Pharm"},{"key":"1056_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00237","volume":"7","author":"A Rouanet","year":"2020","unstructured":"Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Girgis H, et al. Live biotherapeutic products, a road map for safety assessment. Front Med. 2020;7:237. https:\/\/doi.org\/10.3389\/fmed.2020.00237.","journal-title":"Front Med"},{"key":"1056_CR88","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s12276-020-0437-6","volume":"52","author":"M Cordaillat-Simmons","year":"2020","unstructured":"Cordaillat-Simmons M, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020;52:1397\u2013406. https:\/\/doi.org\/10.1038\/s12276-020-0437-6.","journal-title":"Exp Mol Med"},{"key":"1056_CR89","unstructured":"U.S. Food and Drug Administration. Early clinical trials with live biotherapeutic products: Chemistry, manufacturing, and control information; guidance for industry. 2016. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information. Accessed 1 Jan 2026."},{"key":"1056_CR90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4415\/ANN_23_01_09","volume":"59","author":"G Franciosa","year":"2023","unstructured":"Franciosa G, Guida S, Miguel MJG, Hunolstein CV. Live biotherapeutic products and their regulatory framework in Italy and Europe. Ann Ist Super Sanita. 2023;59:56\u201367. https:\/\/doi.org\/10.4415\/ANN_23_01_09.","journal-title":"Ann Ist Super Sanita"},{"key":"1056_CR91","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/gutjnl-2024-334501","volume":"74","author":"CH Tseng","year":"2025","unstructured":"Tseng CH, Wong S, Yu J, Lee YY, Terauchi J, Lai HC, et al. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. Gut. 2025;74:706\u201313. https:\/\/doi.org\/10.1136\/gutjnl-2024-334501.","journal-title":"Gut"},{"key":"1056_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70083","volume":"4","author":"W Wang","year":"2025","unstructured":"Wang W, Bu N, Cao H, Chen N, Chen W, Cheng L, et al. Shaping the future of probiotics, live biotherapeutic products, and fecal microbiota transplantation: 30 scientific recommendations from the CHINAGUT Conference. iMeta. 2025;4:e70083. https:\/\/doi.org\/10.1002\/imt2.70083.","journal-title":"iMeta"},{"key":"1056_CR93","unstructured":"FAO\/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. https:\/\/openknowledge.fao.org\/server\/api\/core\/bitstreams\/8b1233c6-f928-4ff0-85e1-78b2e27c6e4e\/content. Accessed 1 Jan 2026."},{"key":"1056_CR94","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506\u201314. https:\/\/doi.org\/10.1038\/nrgastro.2014.66.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1056_CR95","unstructured":"FDA. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat clostridioides difficile infection not responsive to standard therapies. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota. Accessed 1 Jan 2026."},{"key":"1056_CR96","unstructured":"FDA. BLA Clinical Review Memorandum. 2023. https:\/\/www.fda.gov\/media\/168274\/download. Accessed 1 Jan 2026."},{"key":"1056_CR97","unstructured":"FDA. BLA Approval. 2023. https:\/\/www.fda.gov\/media\/167580\/download. Accessed 1 Jan 2026."}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01056-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01056-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01056-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:18:28Z","timestamp":1781371108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01056-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":97,"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01056-z","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}